Sugi Predict

Sugi Predict / Compounds / SCHEMBL1450299

SCHEMBL1450299

SCHEMBL1450299

Cc1cc(C(=O)Cl)oc1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 4/20 0.49
▸ RAB9A P51151 3/20 0.49
▸ SMN1; SMN2 Q16637 3/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ HPGD P15428 1/20 0.49
▸ TAS1R3 Q7RTX0 2/20 0.46
▸ TAS1R1 Q7RTX1 2/20 0.46
▸ KMT2A Q03164 3/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ ALPG P10696 1/20 0.42
▸ MITF O75030 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ NFKB1 P19838 1/20 0.41
▸ NFKB2 Q00653 1/20 0.41
▸ RELA Q04206 1/20 0.41
▸ ALPL P05186 1/20 0.41
▸ AKR1C3 P42330 1/20 0.41
▸ APEX1 P27695 1/20 0.36
▸ POLB P06746 1/20 0.35
▸ IMPDH2 P12268 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10242709 0.79 ALDH1A1 (0.50) NPC1RAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL700764 0.79 APEX1 (0.55) NPC1RAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL2172078 0.77 NPC1 (0.49) NPC1RAB9ASMN1; SMN2ALDH1A1HPGD
Hydrochloric Acid SCHEMBL5739188 0.76 NPC1 (0.47) NPC1RAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL13181122 0.76 TAS1R3 (0.53) NPC1RAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL20188651 0.74 MAPT (0.56) NPC1RAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL13152217 0.74 NPC1 (0.50) NPC1RAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL14086112 0.74 NPC1 (0.59) NPC1RAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL11840442 0.74 KDM4E (0.31) ALDH1A1HPGDKDM4EMAPT
SCHEMBL1901997 0.72 TAS1R3 (0.58) NPC1RAB9ASMN1; SMN2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024138109-A2 PHENYL-PYRAZOLE CARBOXAMIDE COMPOUNDS ACRIVON THERAPEUTICS, INC. (US) 2024-06-27 — — WO disclosed
CN-112041319-B Triazole, imidazole and pyrrole fused piperazine derivatives and their use as mGlu5Use of modulators of receptors 利康化学与制药工业有限公司 2024-05-14 — — CN disclosed
CN-112341584-B Bio-based benzoxazine resin containing furan amide structure and preparation method thereof 四川轻化工大学 2023-09-08 — — CN disclosed
US-11591337-B2 Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of mGlu5 receptors RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A. (IT) 2023-02-28 — — US disclosed
US-20210047331-A1 TRIAZOLE, IMIDAZOLE AND PYRROLE CONDENSED PIPERAZINE DERIVATIVES AND THEIR USE AS MODULATORS OF mGlu5 RECEPTORS RECORDATI IND CHIMICA E FARMACEUTICA S P A (IT) 2021-02-18 — — US disclosed
CN-112341584-A Bio-based benzoxazine resin containing furan amide structure and preparation method thereof 四川轻化工大学 2021-02-09 — — CN disclosed
CN-112041319-A Triazole, imidazole and pyrrole fused piperazine derivatives and their use as mGlu5Use of modulators of receptors 利康化学与制药工业有限公司 2020-12-04 — — CN disclosed
EP-3743429-A1 TRIAZOLE, IMIDAZOLE AND PYRROLE CONDENSED PIPERAZINE DERIVATIVES AND THEIR USE AS MODULATORS OF mGlu5 RECEPTORS RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. (IT) 2020-12-02 — — EP disclosed
WO-2019145214-A1 TRIAZOLE, IMIDAZOLE AND PYRROLE CONDENSED PIPERAZINE DERIVATIVES AND THEIR USE AS MODULATORS OF mGlu5 RECEPTORS RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A (IT) 2019-08-01 — — WO disclosed
US-8541406-B2 Thiadiazole derivatives for the treatment of neurodegenerative diseases NV REMYND (BE) 2013-09-24 — — US disclosed
US-7910556-B2 PAR-2 agonist KOWA COMPANY, LTD. (JP) 2011-03-22 — — US disclosed
US-20100261707-A9 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2010-10-14 — — US disclosed
US-20090233911-A2 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-09-17 — — US disclosed
US-20090131330-A1 PAR-2 AGONIST KOWA CO., LTD. (JP) 2009-05-21 — — US disclosed
US-20090054410-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-26 — — US disclosed
EP-1845104-A1 PAR-2 AGONIST Kowa Company. Ltd. (JP) 2007-10-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233911-A2 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PARK7 NPC1 77/4885RAB9A 2845/4885SMN1; SMN2 4/4885
US-20210047331-A1 TRIAZOLE, IMIDAZOLE AND PYRROLE CONDENSED PIPERAZINE DERIVATIVES AND THEIR USE AS MODULATORS OF mGlu5 RECEPTORS GRM5, GRIK5, GRIN3A NPC1 2300/4885RAB9A 1808/4885SMN1; SMN2 3258/4885
US-20100261707-A9 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PARK7 NPC1 77/4885RAB9A 2845/4885SMN1; SMN2 4/4885
US-11591337-B2 Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of mGlu5 receptors GRM5, GRIK5, GRM1 NPC1 2081/4885RAB9A 1986/4885SMN1; SMN2 2781/4885
US-20090054410-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PARK7 NPC1 77/4885RAB9A 2845/4885SMN1; SMN2 4/4885
US-20090131330-A1 PAR-2 AGONIST F2RL1, CNR2, FFAR2 NPC1 723/4885RAB9A 2739/4885SMN1; SMN2 4044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.